| The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. | |
| | |
MedLine Citation:
|
PMID: 20880347 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIMS: To investigate whether glucose lowering with the selective sodium glucose transporter 2 (SGLT2) inhibitor dapagliflozin would prevent or reduce the decline of pancreatic function and disruption of normal islet morphology. METHODS: Female Zucker diabetic fatty (ZDF) rats, 7-8 weeks old, were placed on high-fat diet. Dapagliflozin (1 mg/kg/day, p.o.) was administered for ∼33 days either from initiation of high-fat diet or when rats were moderately hyperglycaemic. Insulin sensitivity and pancreatic function were evaluated using a hyperglycaemic clamp in anaesthetized animals (n = 5-6); β-cell function was quantified using the disposition index (DI) to account for insulin resistance compensation. Pancreata from a matched subgroup (n = 7-8) were fixed and β-cell mass and islet morphology investigated using immunohistochemical methods. RESULTS: Dapagliflozin, administered from initiation of high-fat feeding, reduced the development of hyperglycaemia; after 24 days, blood glucose was 8.6 ± 0.5 vs. 13.3 ± 1.3 mmol/l (p < 0.005 vs. vehicle) and glycated haemoglobin 3.6 ± 0.1 vs. 4.8 ± 0.26% (p < 0.003 vs. vehicle). Dapagliflozin improved insulin sensitivity index: 0.08 ± 0.01 vs. 0.02 ± 0.01 in obese controls (p < 0.03). DI was improved to the level of lean control rats (dapagliflozin 0.29 ± 0.04; obese control 0.15 ± 0.01; lean 0.28 ± 0.01). In dapagliflozin-treated rats, β-cell mass was less variable and significant improvement in islet morphology was observed compared to vehicle-treated rats, although there was no change in mean β-cell mass with dapagliflozin. Results were similar when dapagliflozin treatment was initiated when animals were already moderately hyperglycaemic. CONCLUSION: Sustained glucose lowering with dapagliflozin in this model of type 2 diabetes prevented the continued decline in functional adaptation of pancreatic β-cells. |
| | |
Authors:
|
F R Macdonald; J E Peel; H B Jones; R M Mayers; L Westgate; J M Whaley; S M Poucher |
Related Documents
:
|
1526267 - In vitro effect of vanadate on content, secretion and biosynthesis of insulin in isolat... 1371447 - Elevated beta-cell calmodulin produces a unique insulin secretory defect in transgenic ... 20336517 - Generation of functional insulin-producing cells from human embryonic stem cells in vitro. 2023537 - Long-term effects of a high glucose concentration in vitro on the oxidative metabolism ... 15971157 - Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus. 3897287 - Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. e... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 12 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 1004-12 Citation Subset: IM |
Copyright Information:
|
© 2010 AstraZeneca UK Ltd. |
Affiliation:
|
CVGI Discovery, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Correction of insulin sensitivity and glucose disposal after pancreatic islet transplantation: preli...
Next Document: Proof-of-concept trial on the efficacy of sodium tungstate in human obesity.